Anti-Hypertensive Drugs Market is touted to reach USD 41,123.2 million by 2023|Competirors Analysis- Boehringer Engelheim GmbH, Takeda Pharmaceutical Company, Merck KGaA, Johnson & Johnson Services, Inc., Bayer AG and more

Antihypertensive drugs are a class of chemicals capable of lowering high blood pressure or hypertension. Antihypertensive treatment recommended by clinicians and doctors include antihypertensive drugs which can reduce the probability of stroke and myocardial infarction. Different classes of these drugs include beta blockers, angiotensin receptor II antagonists (ARBs), ACE inhibitors, calcium channel blockers, and thiazide diuretics.

Increasing cases of hypertension is the primary driver of the antihypertensive drugs market. This is supported by data provided by the World Health Organization (WHO) which has witnessed the incidence of high blood pressure in the number of adults above the age of 22 to shoot up considerably. Awareness campaigns by government and non-government organizations can net the antihypertensive drugs market much-needed support.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2347

High prevalence of chronic diseases is expected to spike up the production of antihypertensive drugs. According the Centers for Disease Control and Prevention (CDC), nearly 1 in 3 U.S. adults have high blood pressure. Launch of generic versions of patented drugs is likely to fuel the market growth. This is expected to lower the patient treatment costs of high blood pressure and augur well for the antihypertensive drugs market.

Segmentation:

Type-wise, the antihypertensive drugs market is segmented into primary and secondary hypertension. Primary hypertension accounted for a large share of the market in 2017 owing to genetic factors, insulin resistance, and sedentary lifestyle. Secondary hypertension accounted for a smaller market share in the same year. This percentage can fluctuate owing to consumption of cocaine, endocrine disorders, and vascular disorders.

By therapeutic class, the market is segmented into vasodilators, ACE inhibitors, renin inhibitors, diuretics, ARBs, beta-adrenergic blockers, calcium blockers, and others. Diuretics was the leading drug in the antihypertensive drugs market and indicated by maximum number of clinicians for treating hypertension. But ACE inhibitors are expected to grow exponentially owing to the ability of the drug to dilate blood vessels and lower the blood pressure. In addition, ARBs can contribute to market revenue owing to being recommended for hypertension treatment for adults above 55.

Distribution channels in the antihypertensive drugs market include hospital pharmacy, online pharmacy, e-commerce websites & online drug stores, and others. Retail pharmacy accounted for the lion’s share of the market in 2017. This can be due to setups of pharmacy outlets at ideal locations. But the segment can lose its position to e-commerce websites & online stores by 2023. This can be attributed to its customer-first model and adoption of digitization which cater to demands of patients.

Regional Analysis:

The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.

The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.

The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347

Competitive Analysis:

Prominent players to get profiled in the antihypertensive drugs market report are United Therapeutics Corporation (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Sanofi S.A. (France), Merck KGaA (Germany), and Bayer AG (Germany).

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.